Global Reduction of H3K4me3 Improves Chemotherapeutic Efficacy for Pediatric Ependymomas1

[1]  Wei Sun,et al.  Up‐regulated WDR5 promotes gastric cancer formation by induced cyclin D1 expression , 2018, Journal of cellular biochemistry.

[2]  S. Armstrong,et al.  A Non-catalytic Function of SETD1A Regulates Cyclin K and the DNA Damage Response , 2018, Cell.

[3]  D. Johnston,et al.  Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome , 2017, Acta Neuropathologica.

[4]  K. Aldape,et al.  The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants , 2016, Acta Neuropathologica.

[5]  T. Lei,et al.  Histone modification as a drug resistance driver in brain tumors , 2016, Oncology and Translational Medicine.

[6]  P. Ferroli,et al.  Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma. , 2016, Neuro-oncology.

[7]  T. Hortobágyi,et al.  Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S. Maheswaran,et al.  SETD1A induced miRNA network suppresses the p53 gene expression module , 2016, Cell cycle.

[9]  Ben S. Wittner,et al.  Supplementary Information Supplementary Figures , 2022 .

[10]  Lin Wang,et al.  Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies , 2015, Clinical Cancer Research.

[11]  D. Ellison,et al.  An in vivo screen identifies ependymoma oncogenes and tumor-suppressor genes , 2015, Nature Genetics.

[12]  Gary D Bader,et al.  Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. , 2015, Cancer cell.

[13]  Jing Liang,et al.  Chromatin architecture reorganization during stem cell differentiation , 2015, Nature.

[14]  K. Brown,et al.  Histone Methyltransferase hSETD1A Is a Novel Regulator of Metastasis in Breast Cancer , 2014, Molecular Cancer Research.

[15]  R. Riccardi,et al.  Ependymoma stem cells are highly sensitive to temozolomide in vitro and in orthotopic models. , 2014, Neuro-oncology.

[16]  Chin-Hsing Annie Lin,et al.  Epigenetic Regulation by Chromatin Activation Mark H3K4me3 in Primate Progenitor Cells within Adult Neurogenic Niche , 2014, Scientific Reports.

[17]  V. Amani,et al.  Molecular sub-group-specific immunophenotypic changes are associated with outcome in recurrent posterior fossa ependymoma , 2014, Acta Neuropathologica.

[18]  P. Burger,et al.  Benefit from prolonged dose-intensive chemotherapy for infants with malignant brain tumors is restricted to patients with ependymoma: a report of the Pediatric Oncology Group randomized controlled trial 9233/34. , 2014, Neuro-oncology.

[19]  Gary D Bader,et al.  Epigenomic alterations define lethal CIMP-positive ependymomas of infancy , 2014, Nature.

[20]  Li Ding,et al.  C11orf95-RELA fusions drive oncogenic NF-κB signaling in ependymoma , 2014, Nature.

[21]  F. Kaye,et al.  hSETD1A regulates Wnt target genes and controls tumor growth of colorectal cancer cells. , 2014, Cancer research.

[22]  A. Ebrahimi,et al.  Prognostic relevance of global histone 3 lysine 9 acetylation in ependymal tumors. , 2013, Journal of neurosurgery.

[23]  Sathish Kumar Mungamuri,et al.  Chromatin modifications sequentially enhance ErbB2 expression in ErbB2-positive breast cancers. , 2013, Cell reports.

[24]  Min Gyu Lee,et al.  Histone H3 lysine 4 methyltransferases and demethylases in self-renewal and differentiation of stem cells , 2013, Cell & Bioscience.

[25]  H. Gabra,et al.  Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells , 2013, Oncogene.

[26]  Jennifer E. Phillips-Cremins,et al.  Architectural Protein Subclasses Shape 3D Organization of Genomes during Lineage Commitment , 2013, Cell.

[27]  Steven J. M. Jones,et al.  Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma , 2013, Acta Neuropathologica.

[28]  I. Pogribny,et al.  Modifying metabolically sensitive histone marks by inhibiting glutamine metabolism affects gene expression and alters cancer cell phenotype , 2012, Epigenetics.

[29]  P. L. Bergsagel,et al.  Molecular pathogenesis of multiple myeloma and its premalignant precursor. , 2012, The Journal of clinical investigation.

[30]  C. Hawkins,et al.  Survival benefit for pediatric patients with recurrent ependymoma treated with reirradiation. , 2012, International journal of radiation oncology, biology, physics.

[31]  Gary D Bader,et al.  Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. , 2011, Cancer cell.

[32]  Amar Gajjar,et al.  Cross-species genomics matches driver mutations and cell compartments to model ependymoma , 2010, Nature.

[33]  J. Lowe,et al.  Pediatric Ependymoma: Biological Perspectives , 2009, Molecular Cancer Research.

[34]  T. Merchant,et al.  Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. , 2009, The Lancet. Oncology.

[35]  M. D. Den Boer,et al.  Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective. , 2008, Neuro-oncology.

[36]  Peng Fei Wang,et al.  Molecular Regulation of H3K4 Trimethylation by Wdr82, a Component of Human Set1/COMPASS , 2008, Molecular and Cellular Biology.

[37]  D. Skalnik,et al.  Identification and Characterization of the Human Set1B Histone H3-Lys4 Methyltransferase Complex* , 2007, Journal of Biological Chemistry.

[38]  P. Lichter,et al.  Identification of Gains on 1q and Epidermal Growth Factor Receptor Overexpression as Independent Prognostic Markers in Intracranial Ependymoma , 2006, Clinical Cancer Research.

[39]  Amar Gajjar,et al.  Radial glia cells are candidate stem cells of ependymoma. , 2005, Cancer cell.

[40]  Jef D Boeke,et al.  Regulated nucleosome mobility and the histone code , 2004, Nature Structural &Molecular Biology.

[41]  L. Gerschenson,et al.  Interactions of the allogeneic effector leukemic T cell line, TALL-104, with human malignant brain tumors. , 2004, Neuro-oncology.

[42]  S. Khorasanizadeh.  The Nucleosome From Genomic Organization to Genomic Regulation , 2004, Cell.

[43]  T. Curran,et al.  ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  D. B. Paul,et al.  The human leukemic T-cell line, TALL-104, is cytotoxic to human malignant brain tumors and traffics through brain tissue: implications for local adoptive immunotherapy. , 2000, Cancer research.

[45]  E. Bouffet,et al.  Chemotherapy for intracranial ependymomas , 1999, Child's Nervous System.

[46]  McDonald,et al.  Nuclear expression of p53, p21 and cyclin D1 is increased in bronchioloalveolar carcinoma , 1999, Histopathology.

[47]  J. Barnholtz-Sloan,et al.  American Brain Tumor Association Adolescent and Young Adult Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. , 2016, Neuro-oncology.

[48]  P. Lichter,et al.  Identification of Gains on 1 q and Epidermal Growth Factor Receptor Overexpression as Independent PrognosticMarkers in Intracranial Ependymoma , 2006 .

[49]  Tony Kouzarides,et al.  Histone H3 lysine 4 methylation patterns in higher eukaryotic genes , 2004, Nature Cell Biology.

[50]  Anushya Muruganujan,et al.  PANTHER: a browsable database of gene products organized by biological function, using curated protein family and subfamily classification , 2003, Nucleic Acids Res..